| 601139 | 深圳燃 | 0.92 | 0.30 | 6.57 | 6.61 | 0.63 | | --- | --- | --- | --- | --- | --- | --- | | | 气 | | | | | | | 002813 | 路畅科 | 1.36 | 2.69 | 24.37 | 24.52 | 0.63 | | | 技 | | | | | | | 000966 | 长源电 | 0.66 | 0.71 | 4.58 | 4.60 | 0.45 | | | 力 | | | | | | | 601158 | 重庆水 | 0.43 | 0.12 | 4.70 | 4.72 | 0.35 | | | 务 | | | | | | | 000875 | 吉电股 | 1.35 | 0.84 | 5.24 | 5.25 | 0.25 | | | 份 | | | | | | | 002032 | 苏泊尔 | 0.21 | 0.08 | 51.32 | 51.39 | 0.14 | | 002157 | 正邦科 | 0.70 | 0.38 | 2.87 | 2.87 | 0.12 | | | 技 | | ...

Market Overview - The Shanghai Composite Index is at 3636.69 points, slightly down by 0.08%, with a total trading volume of 802.9 billion yuan [1] - 21 A-shares have surpassed their annual line today, with notable stocks showing significant deviation rates [1] Stocks with Significant Deviation Rates - *ST Yitong has a deviation rate of 2.59%, with a price increase of 4.74% and a turnover rate of 2.93% [1] - Landun Optoelectronics shows a deviation rate of 1.97%, with a price increase of 6.14% and a turnover rate of 10.07% [1] - Guodian Power has a deviation rate of 1.53%, with a price increase of 1.52% and a turnover rate of 0.48% [1] Stocks with Smaller Deviation Rates - Pumen Technology and Jinlang Technology have just crossed the annual line with minor deviation rates of 0.06% and 0.13% respectively [2] - Longi Green Energy has a deviation rate of 0.20%, with a price increase of 0.25% [2]

Group 1 - Xianju Pharmaceutical Co., Ltd. has experienced a decline in stock price for seven consecutive trading days, with a cumulative drop of -5.94% [1] - The company, founded in 1972, aims to become one of the top ten steroid drug suppliers globally and focuses on the steroid hormone sector [1] - In the second quarter of this year, Xianju Pharmaceutical was added to the top ten shareholders of the Xinchuan He Feng three-year holding mixed fund, which has achieved a year-to-date return of 20.55% [1] Group 2 - Yang Shijin and Zhu Kefei are the current fund managers of the Xinchuan He Feng three-year holding mixed fund [4] - Zhu Kefei has been managing the fund since July 2, 2025, and has a tenure of 36 days with a return of 8.40% [3] - Xingsheng Global Fund Management Co., Ltd. was established in September 2003 and is co-owned by Xinyi Securities Co., Ltd. and Global Life Insurance International Company [3]

仙琚制药（002332.SZ）8月5日在投资者互动平台表示，公司已申报在评审新产品包括雌二醇片、甲磺 酸倍他司汀片、噻托溴铵喷雾剂、黄体酮凝胶等。创新药研发一般会经历从靶点识别、化合物发现、临 床前研究、临床实验等多个阶段。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：本公司除了奥美克松钠还有其它什么创新药和仿制药 在审批中？ ...

Market Overview - As of 10:29 AM today, the Shanghai Composite Index stands at 3592.77 points, above the annual line, with a change of 0.30% [1] - The total trading volume of A-shares today is 857.68 billion yuan [1] Stocks Breaking Annual Line - A total of 27 A-shares have surpassed the annual line today, with notable stocks including: - Opcon Vision (300595) with a deviation rate of 9.58% - Mars (300894) with a deviation rate of 6.80% - Xianju Pharmaceutical (002332) with a deviation rate of 3.03% [1] Deviation Rate Rankings - The following stocks have the highest deviation rates from the annual line: - Opcon Vision: Today's increase of 12.38%, turnover rate of 3.83%, annual line at 16.41 yuan, latest price at 17.98 yuan [1] - Mars: Today's increase of 8.18%, turnover rate of 8.48%, annual line at 13.62 yuan, latest price at 14.55 yuan [1] - Xianju Pharmaceutical: Today's increase of 5.12%, turnover rate of 5.68%, annual line at 10.36 yuan, latest price at 10.67 yuan [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the annual line include: - Beiqi Blue Valley (600733) with a deviation rate of 0.03% - Qianhe Flavor (603027) with a deviation rate of 0.05% - Luyang Energy (002088) with a deviation rate of 0.15% [2]

证券代码：002332 证券简称：仙琚制药 公告编号：2025-029 浙江仙琚制药股份有限公司 关于噻托溴铵吸入喷雾剂药品注册申请获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局下发的噻托溴铵吸入喷雾剂境内生产药品注册受理通知书，现将相关情况 公告如下： 品注册工作进入了审评阶段，公司将积极推进后续相关工作，如顺利通过审批将 丰富公司的产品线，有利于提升公司的市场竞争力。药品注册审批工作流程有一 定时间周期，存在不确定性因素，敬请广大投资者审慎决策，注意投资风险。 二、噻托溴铵吸入喷雾剂的相关情况 噻托溴铵吸入喷雾剂，规格为每瓶 60 喷，每喷递送剂量为噻托溴铵 2.5μg （按 C₁₉H₂₂NO₄S₂计），药液浓度含噻托溴铵 0.2262mg/ml（按 C₁₉H₂₂NO₄S₂计）， 参比制剂为原研药噻托溴铵吸入喷雾剂，持证商是 Boehringer Ingelheim International GmbH，商品名为 Spiriva® Respimat®。适应症为用于慢 ...

Group 1 - The company, Xianju Pharmaceutical (002332.SZ), has received a drug registration acceptance notice from the National Medical Products Administration for the production of Tiotropium Bromide Inhalation Spray [1] - The specifications of the Tiotropium Bromide Inhalation Spray include a delivery dose of 2.5μg per spray and a liquid concentration of 0.2262mg/ml [1] - The drug registration process has entered the review stage, and successful approval will enhance the company's product line and market competitiveness [1] Group 2 - The drug registration approval process has an uncertain timeline, which may affect investment decisions [1]

一、增资概述 浙江萃泽医药科技有限公司（以下简称"萃泽医药"）系浙江仙琚制药股份 有限公司（以下简称"公司"）的参股公司，公司持有其 37.3879%的股权。近 日，公司收到萃泽医药拟增加注册资本的通知，考虑到经营需求，萃泽医药注册 资本拟由 1529.0243 万元增资到 1618.0152 万元，拟增加注册资本 88.9909 万元， 增资价格为 37.0825 元/股。公司结合实际经营情况，拟放弃本次股权增资的优 先认缴出资权。 本次增资拟由以下 5 家投资方参与：仙居县海纳包装有限公司出资 1200 万 元人民币，王焕勇出资 900 万元人民币，王宝军出资 600 万元人民币，郑旭芬出 资 300 万元人民币，楼晓炯出资 300 万元人民币。拟参与增资的 5 家认购方以现 金出资合计 3300 万元人民币,认购萃泽医药的新增注册资本 88.9909 万元。本次 增资完成后，公司持有萃泽医药的股权比例由原来的 37.3879%降至 35.3316%。 本次放弃萃泽医药增资优先认购权事项已经公司第八届董事会第十四次会 议审议通过，根据《公司章程》、公司《投资管理制度》规定，本次放弃萃泽医 药增资优先认购权 ...

浙江仙琚制药股份有限公司（以下简称"公司"）第八届董事会第十四次会 议通知已于 2025 年 6 月 19 日以电子邮件方式向公司全体董事发出，会议于 2025 年 6 月 25 日以通讯方式召开。本次会议应参加董事 9 名，实际参加董事 9 名， 会议由公司董事长张宇松先生召集并主持。本次会议的召集、召开符合《中华人 民共和国公司法》和《公司章程》的有关规定。全体与会董事以记名投票方式通 过以下决议： 证券代码：002332 证券简称：仙琚制药 公告编号：2025-027 浙江仙琚制药股份有限公司 第八届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 董事会 2025 年 6 月 26 日 会议以 9 票同意，0 票弃权，0 票反对，审议通过了《关于放弃参股公司增 资扩股优先认缴出资权的议案》。 《关于放弃参股公司增资扩股优先认缴出资权的公告》详见 2025 年 6 月 26 日的《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网 （www.cninfo.com.cn）。 特此公告。 浙江仙琚制药股份有限公司 ...

Core Viewpoint - The recent penalty imposed by the State Administration for Market Regulation has exposed a hidden monopoly network in the pharmaceutical industry, with significant financial repercussions for the involved parties [1]. Group 1: Monopoly Scheme - A gathering organized by an individual named Guo in November 2021 led to a verbal agreement among four pharmaceutical companies to stop price competition and collectively raise prices [2]. - To evade regulatory scrutiny, the companies coordinated price hikes through Guo, using communication methods such as WeChat and phone calls [2]. Group 2: Price Surge - Following the agreement, the four companies collectively halted supply in January 2022, causing a severe market supply shortage [3]. - The price of the raw material dexamethasone skyrocketed from 8,000 yuan per kilogram to 13,800 yuan, marking a 72% increase [3]. - The price of dexamethasone injection surged from 0.35 yuan per unit to nearly 100 yuan, with some hospitals in Guangxi purchasing it at 60 yuan per unit, reflecting an alarming increase [3]. Group 3: Penalties and Legal Framework - The leniency policy in antitrust cases played a crucial role, with Tianyao Pharmaceutical receiving an 80% reduction in fines after self-reporting and providing key evidence, resulting in a total penalty of 69.19 million yuan [4]. - In contrast, Xianju Pharmaceutical faced a maximum fine of nearly 195 million yuan due to its failure to apply for leniency [4]. - All responsible individuals from the four companies were fined 600,000 yuan each [4]. Group 4: Regulatory Environment - The case is part of a broader trend, with multiple antitrust cases in the pharmaceutical sector being investigated in recent years, including those involving acetic acid and other raw materials [5]. - The regulatory framework has been strengthened with the introduction of the "Raw Material Drug Antitrust Guidelines" in 2021 and the "Drug Sector Antitrust Guidelines" set for 2025, establishing a comprehensive regulatory system [5]. - Antitrust enforcement is increasingly focused on essential sectors like pharmaceuticals, with new major cases leading to price reductions of up to 62% for involved drugs [5].